256P Difference of immunological status and response to immune checkpoint inhibitor between recurrent and de novo stage IV HER2-negative breast cancer in NEWBEAT trial (WJOG9917BTR)
Ozaki, Y., Kitano, S., Yamashita, M., Ikarashi, D., Tsurutani, J., Iwasa, T., Takahashi, M., Mukohara, T., Masuda, N., Futamura, M., Minami, H., Matsumoto, K., Tanabe Hashimoto, Y., Kawabata, H., Yoshimura, K., Takano, T.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
2061P Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Yamamoto, K., Hashimoto, Y. Tanabe, Nonogaki, K., Kono, H., Toda, E., Okumura, H., Ozaki, H., Kuno, M., Watanabe, S., Takemura, K., Yamanaka, T., Kizawa, R., Yamaguchi, T., Tanaka, K., Kobayashi, Y., Ogura, T., Tamura-Hatano, N., Kawabata, H., Suyama, K., Miura, Y.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
1245PEosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Kizawa, R, Miura, Y, Oda, Y, Nagaoka, Y, Masuda, J, Ozaki, Y, Kondoh, C, Moriguchi, S, Takahashi, Y, Ogawa, K, Hashimoto, Y Tanabe, Taniguchi, S, Okaneya, T, Kishi, A, Hayashi, N, Takaya, H, Takano, T
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1245P - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Kizawa, R., Miura, Y., Oda, Y., Nagaoka, Y., Masuda, J., Ozaki, Y., Kondoh, C., Moriguchi, S., Takahashi, Y., Ogawa, K., Hashimoto, Y Tanabe, Taniguchi, S., Okaneya, T., Kishi, A., Hayashi, N., Takaya, H., Takano, T.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Kizawa, R., Miura, Y., Oda, Y., Nagaoka, Y., Masuda, J., Ozaki, Y., Kondoh, C., Moriguchi, S., Takahashi, Y., Ogawa, K., Hashimoto, Y Tanabe, Taniguchi, S., Okaneya, T., Kishi, A., Hayashi, N., Takaya, H., Takano, T.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
188P A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor-positive (HR+), HER2-low metastatic breast cancer (mBC)
Ueno, N.T., Cottone, F., Dunton, K., Cardoso, F., Yamashita, T., Losada, M.J. Vidal, Niikura, N., Zagouri, F., Sohn, J., Gombos, A., Im, S-A., Pierga, J-Y., Krop, I., Hashimoto, Y. Tanabe, Kim, J.H., Gori, S., Jacot, W., Bauer, R., Aguilar, C. Orbegoso, Modi, S.
Published in ESMO open (01.05.2024)
Published in ESMO open (01.05.2024)
Get full text
Journal Article